

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C07D 491/052, A61K 31/44 // (C07D 491/052, 311:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/41257</p> <p>(43) International Publication Date: 19 August 1999 (19.08.99)</p>
<p>(21) International Application Number: PCT/US99/03210</p> <p>(22) International Filing Date: 15 February 1999 (15.02.99)</p> <p>(30) Priority Data: 09/023,913 13 February 1998 (13.02.98) US</p> <p>(71) Applicants: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US). LIGAND PHARMACEUTICALS, INC. [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: COUGHLAN, Michael, J.; 307 Fairfax Lane, Grayslake, IL 60030 (US). KORT, Michael, E.; 507 N. Green Avenue, Lake Bluff, IL 60044 (US). EDWARDS, James, P.; 8723 Hesby Court, San Diego, CA 92129 (US). JONES, Todd, K.; 546 Marview Drive, Solana Beach, CA 92075 (US).</p> <p>(74) Agents: STEELE, Gregory, W. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: GLUCOCORTICOID-SELECTIVE ANTIINFLAMMATORY AGENTS</p>		
<div style="text-align: center;">  <p>(I)</p> </div>		
<p>(57) Abstract</p> <p>Compounds having Formula (I) are useful for partially or fully antagonizing, repressing, agonizing, or modulating the glucocorticoid receptor in a mammal and treating immune, autoimmune and inflammatory diseases in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of inhibiting immune or autoimmune diseases in a mammal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

GLUCOCORTICOID-SELECTIVE ANTIINFLAMMATORY AGENTS

Technical Field

The present invention relates to glucocorticoid receptor-selective benzopyranof[3,4-f]quinolines that are useful for treating immune or autoimmune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation, inflammatory disease, immune, and autoimmune diseases in a mammal.

Background of The Invention

Intracellular receptors (IR's) are a class of structurally related proteins involved in the regulation of gene expression. The steroid hormone receptors are a subset of this superfamily whose natural ligands are typically comprised of endogenous steroids such as estradiol, progesterone, and cortisol. Man-made ligands to these receptors play an important role in human health and, of these receptors, the glucocorticoid receptor (GR) has an essential role in regulating human physiology and immune response. Steroids which interact with GR have been shown to be potent antiinflammatory agents. Despite this benefit, steroidal GR ligands are not selective. Side effects associated with chronic dosing are believed to be the result of cross-reactivity with other steroid receptors such as estrogen, progesterone, androgen, and mineralocorticoid receptors which have somewhat homologous ligand binding domains.

Selective GR repressors, agonists, partial agonists and antagonists of the present disclosure can be used to influence the basic, life-sustaining systems of the body, including carbohydrate, protein and lipid metabolism, and the functions of the cardiovascular, kidney, central nervous, immune, skeletal muscle, and other organ and tissue systems. In this regard, GR modulators have proven useful in the treatment of inflammation, tissue rejection, auto-immunity, various malignancies, such as leukemias and lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome.

GR modulators are especially useful in disease states involving systemic inflammation such as inflammatory bowel disease, systemic lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation,


hepatitis, and cirrhosis. GR active compounds have also been used as immunostimulants and repressors, and as wound healing and tissue repair agents.

GR modulators have also found use in a variety of topical diseases such as inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, systemic lupus erythematosus, dermatomyositis, herpes gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitis, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma.

Selective antagonists of the glucocorticoid receptor have been unsuccessfully pursued for decades. These agents would potentially find application in several disease states associated with Human Immunodeficiency Virus (HIV), cell apoptosis, and cancer including, but not limited to, Kaposi's sarcoma, immune system activation and modulation, desensitization of inflammatory responses, IL-1 expression, anti-retroviral therapy, natural killer cell development, lymphocytic leukemia, and treatment of retinitis pigmentosa. Cognitive and behavioral processes are also susceptible to glucocorticoid therapy where antagonists would potentially be useful in the treatment of processes such as cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome, schizophrenia, stroke, sleep disorders, and anxiety.

Summary of The Invention

In one embodiment of the present invention are compounds represented by Formula I



or pharmaceutically acceptable salts or prodrugs thereof, where the symbol --- represents a single or double bond, provided that no two double bonds are in adjacent positions;

A is $-L_1-R_A$ where L_1 is selected from

(1) a covalent bond,

- (2) -O-,
(3) -S(O)_t- where t is 0, 1, or 2,
(4) -C(X)-,
(5) -NR₇- where R₇ is selected from
- 5 (a) hydrogen,
(b) aryl
(c) cycloalkyl of three to twelve carbons,
(d) alkanoyl where the alkyl part is one to twelve carbons,
(e) alkoxycarbonyl where the alkyl part is one to twelve carbons,
10 (f) alkoxycarbonyl where the alkyl part is one to twelve carbons and is substituted by 1 or 2 aryl groups,
(g) alkyl of one to twelve carbons,
(h) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
15 (i) alkenyl of three to twelve carbons,
provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
(j) alkynyl of three to twelve carbons,
20 provided that a carbon of a carbon-carbon triple bond is not attached directly to nitrogen,
- (6) -NR₈C(X)NR₉- where X is O or S and R₈ and R₉ are independently selected from
- 25 (a) hydrogen,
(b) aryl,
(c) cycloalkyl of three to twelve carbons,
(d) alkyl of one to twelve carbons,
(e) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
30 (f) alkenyl of three to twelve carbons,
provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
(g) alkynyl of three to twelve carbons,
35 provided that a carbon of a carbon-carbon triple bond is not attached directly to nitrogen,
- (7) -X'C(X)- where X is previously defined and X' is O or S,

- (8) $-C(X)X'-$,
 (9) $-X'C(X)X''-$ where X and X' are previously defined and X'' is O or S,
 provided that when X is O, at least one of X' or X'' is O,
 5 (10) $-NR_8C(X)-$,
 (11) $-C(X)NR_8-$,
 (12) $-NR_8C(X)X'-$,
 (13) $-X'C(X)NR_8-$,
 (14) $-SO_2NR_8-$,
 10 (15) $-NR_8SO_2-$, and
 (16) $-NR_8SO_2NR_9-$
 where (6)-(16) are drawn with their right ends attached to R_A and R_A is selected from
 (1) $-OH$,
 15 (2) $-OG$ where G is a $-OH$ protecting group,
 (3) $-SH$,
 (4) $-CN$,
 (5) halo,
 (6) haloalkoxy of one to twelve carbons,
 20 (7) perfluoroalkoxy of one to twelve carbons,
 (8) $-CHO$,
 (9) $-NR_7R_7'$ where R_7 is defined previously and R_7' is selected from
 (a) hydrogen,
 (b) aryl,
 25 (c) cycloalkyl of three to twelve carbons,
 (d) alkanoyl where the alkyl part is one to twelve carbons,
 (e) alkoxycarbonyl where the alkyl part is one to twelve carbons,
 (f) alkoxycarbonyl where the alkyl part is one to twelve carbons and is substituted by 1 or 2 aryl groups,
 30 (g) alkyl of one to twelve carbons,
 (h) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
 (i) alkenyl of three to twelve carbons,
 35 provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
 (j) alkynyl of three to twelve carbons,

provided that a carbon of a carbon-carbon triple bond is not attached directly to nitrogen,

(10) $-C(X)NR_8R_9$,

(11) $-OSO_2R_{11}$ where R_{11} is selected from

- 5 (a) aryl,
- (b) cycloalkyl of three to twelve carbons,
- (c) alkyl of one to twelve carbons,
- (d) alkyl of one to twelve carbons substituted with 1, 2, 3, or 4 halo substituents, and

10 (e) perfluoroalkyl of one to twelve carbons,

provided that when R_A is (1)-(11), L_1 is a covalent bond,

(12) alkyl of one to twelve carbons,

(13) alkenyl of two to twelve carbons,

15 provided that a carbon of a carbon-carbon double bond is not attached directly to L_1 when L_1 is other than a covalent bond,

(14) alkynyl of two to twelve carbons,

provided that a carbon of a carbon-carbon triple bond is not attached directly to L_1 when L_1 is other than a covalent bond,

where (12), (13), and (14) can be optionally substituted with 1, 2, or 3 substituents —

20 independently selected from

(a) alkoxy of one to twelve carbons,

(b) $-OH$,

provided that no two $-OH$ groups are attached to the same carbon,

(c) $-SH$,

25 provided that no two $-SH$ groups are attached to the same carbon,

(d) $-CN$,

(e) halo,

(f) $-CHO$,

(g) $-NO_2$,

30 (h) haloalkoxy of one to twelve carbons,

(i) perfluoroalkoxy of one to twelve carbons,

(j) $-NR_7R_{7'}$,

(k) $=NNR_7R_{7'}$,

35 (l) $-NR_7NR_{7'}R_{7''}$ where R_7 and $R_{7'}$ are defined previously and $R_{7''}$ is selected from

(i) hydrogen,

(ii) aryl,

- (iii) cycloalkyl of three to twelve carbons,
- (vi) alkanoyl where the alkyl part is one to twelve carbons,
- (v) alkoxycarbonyl where the alkyl part is one to twelve carbons,
- 5 (vi) alkoxycarbonyl where the alkyl part is one to twelve carbons substituted by 1 or 2 aryl groups,
- (vii) alkyl of one to twelve carbons,
- (viii) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
- 10 (ix) alkenyl of three to twelve carbons, provided that a carbon-carbon double bond is not attached directly to nitrogen, and
- (x) alkynyl of three to twelve carbons, provided that a carbon-carbon triple bond is not attached directly to nitrogen,
- 15 (m) $-\text{CO}_2\text{R}_{10}$ where R_{10} is selected from
 - (i) aryl,
 - (ii) aryl substituted with 1, 2, or 3 alkyl of one to twelve carbon substituents,
 - (ii) cycloalkyl of three to twelve carbons,
 - (iii) alkyl of one to twelve carbons, and
 - (iv) alkyl of one to twelve carbons substituted with aryl or cycloalkyl of three to twelve carbons,
- 20 (n) $-\text{C}(\text{X})\text{NR}_8\text{R}_9$,
- (o) $=\text{N}-\text{OR}_{10}$,
- (p) $=\text{NR}_{10}$,
- (q) $-\text{S}(\text{O})_t\text{R}_{10}$,
- (r) $-\text{X}'\text{C}(\text{X})\text{R}_{10}$,
- 30 (s) $(=\text{X})$, and
- (t) $-\text{OSO}_2\text{R}_{11}$,
- (15) cycloalkyl of three to twelve carbons,
- (16) cycloalkenyl of four to twelve carbons, provided that a carbon of a carbon-carbon double bond is not attached directly to L_1 when L_1 is other than a covalent bond,
- 35 where (15) and (16) can be optionally substituted with 1, 2, 3, or 4 substituents independently selected from

- (a) alkyl of one to twelve carbons,
 - (b) aryl,
 - (c) alkoxy of one to twelve carbons,
 - (d) halo, and
 - 5 (e) -OH,
- provided that no two -OH groups are attached to the same carbon,
- (17) perfluoroalkyl of one to twelve carbons,
 - (18) aryl, and
 - (19) heterocycle
- 10 where (18) and (19) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
- (a) alkyl of one to twelve carbons,
 - (b) alkanoyloxy where the alkyl part is one to twelve carbons,
 - (c) alkoxycarbonyl where the alkyl part is one to twelve carbons,
 - 15 (d) alkoxy of one to twelve carbons,
 - (e) halo,
 - (f) -OH,
- provided that no two -OH groups are attached to the same carbon,
- (g) thioalkoxy of one to twelve carbons,
 - 20 (h) perfluoroalkyl of one to twelve carbons,
 - (i) -NR₇R₇,
 - (j) -CO₂R₁₀,
 - (k) -OSO₂R₁₁, and
 - (l) (=X);

25

R₁, R₂, R₃, and R₄ are independently hydrogen or A; or

R₁ and R₂ together are -X*-Y*-Z*- where X* is -O- or -CH₂-, Y* is -C(O)- or -(C(R₁₂)(R₁₃))_v - where R₁₂ and R₁₃ are independently hydrogen or alkyl of one to
 30 twelve carbons and v is 1, 2, or 3, and Z* is selected from -CH₂-, -CH₂S(O)_r-, -CH₂O-, -CH₂NR₇-, -NR₇-, and -O-;

L₂ is selected from

- (1) a covalent bond,
- 35 (2) alkylene of one to twelve carbons,
- (3) alkylene of one to twelve carbons substituted with 1 or 2 substituents independently selected from

- (a) spiroalkyl of three to eight carbon atoms,
(b) spiroalkenyl of five or eight carbon atoms,
(c) oxo,
(d) halo, and
5 (e) -OH,
provided that no two -OH groups are attached to the same carbon,
(4) alkynylene of two to twelve carbons,
(5) -NR₇-,
(6) -C(X)-,
10 (7) -O-, and
(8) -S(O)_r-; and

R₅ is selected from

- (1) halo,
15 (2) -C(=NR₇)OR₁₀,
(3) -CN,
provided that when R₅ is (1), (2), or (3), L₂ is a covalent bond,
(4) alkyl of one to twelve carbons,
(5) alkynyl two to twelve carbons,
20 provided that a carbon of a carbon-carbon triple bond is not attached directly
to L₃ when L₃ is other than a covalent bond,
(6) cycloalkyl of three to twelve carbons,
(7) heterocycle,
(8) aryl
25 where (4)-(8) can be optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from
(a) -OH,
provided that no two -OH groups are attached to the same carbon,
(b) -SH,
30 provided that no two -SH groups are attached to the same carbon,
(c) -CN,
(d) halo,
(e) -CHO,
(f) -NO₂,
35 (g) haloalkoxy of one to twelve carbons,
(h) perfluoroalkoxy of one to twelve carbons,
(i) -NR₈R₉ where R₈ and R₉ are selected from

- (i) hydrogen,
- (ii) alkanoyl where the alkyl part is one to twelve carbons,
- (iii) alkoxycarbonyl where the alkyl part is one to twelve carbons,
- (iv) alkoxycarbonyl where the alkyl part is one to twelve carbons
and is substituted with 1 or 2 phenyl substituents,
- (v) cycloalkyl of three to twelve carbons,
- (vi) alkyl of one to twelve carbons,
- (vii) alkyl of one to twelve carbons substituted with 1, 2, or 3
substituents independently selected from
alkoxy of one to twelve carbons,
cycloalkyl of three to twelve carbons, and
aryl,
- (viii) alkenyl of three to twelve carbons,
provided that a carbon of a carbon-carbon double bond is
not directly attached to nitrogen,
- (ix) alkynyl of three to twelve carbons,
provided that a carbon of a carbon-carbon triple bond is not
directly attached to nitrogen,
- (x) aryl,
- (xi) aryl substituted with 1, 2, 3, 4, or 5 substituents
independently selected from
alkyl of one to twelve carbons,
alkanoyloxy where the alkyl part is one to twelve carbons,
alkoxycarbonyl where the alkyl part is one to twelve carbons,
alkoxy of one to twelve carbons,
halo,
-OH
provided that no two -OH groups are attached to the same
carbon,
thioalkoxy of one to twelve carbons,
perfluoroalkyl of one to twelve carbons,
-NR₇R₇,
-CO₂R₁₀,
-OSO₂R₁₁, and
(=X), or

R₈ and R₉ together with the nitrogen atom to which they are
attached form a ring selected from

- (i) aziridine,
- (ii) azetidine,
- (iii) pyrrolidine,
- (iv) piperidine,
- 5 (v) pyrazine,
- (vi) morpholine,
- (vii) thiomorpholine, and
- (viii) thiomorpholine sulfone

where (i)-(viii) can be optionally substituted with 1, 2, or 3 alkyl of
 10 one to twelve carbon substituents,

- (j) $=\text{NNR}_8\text{R}_9$,
- (k) $-\text{NR}_7\text{NR}_8\text{R}_9$,
- (l) $-\text{CO}_2\text{R}_8$,
- (m) $-\text{C}(\text{X})\text{NR}_8\text{R}_9$,
- 15 (n) $=\text{N}-\text{OR}_8$,
- (o) $=\text{NR}_8$,
- (p) $-\text{S}(\text{O})_t\text{R}_{10}$,
- (q) $-\text{X}'\text{C}(\text{X})\text{R}_8$,
- (r) $(=\text{X})$,
- 20 (s) $-\text{O}-(\text{CH}_2)_q-\text{Z}-\text{R}_{10}$ where R_{10} is defined previously, q is 1, 2, or 3,
 and Z is O or $-\text{S}(\text{O})_t$,
- (t) $-\text{OC}(\text{X})\text{NR}_8\text{R}_9$,
- (u) $-\text{OSO}_2\text{R}_{11}$,
- (v) alkanoyloxy where the alkyl group is one to twelve carbons,
- 25 (w) $-\text{L}_\text{B}\text{R}_{30}$ where L_B is selected from

- (i) a covalent bond,
- (ii) $-\text{O}-$,
- (iii) $-\text{S}(\text{O})_t-$, and
- (iv) $-\text{C}(\text{X})-$ and

30 R_{30} is selected from

- (i) alkyl of one to twelve carbons,
- (ii) alkenyl of one to twelve carbons,
 provided that a carbon of a carbon-carbon double bond is not
 attached directly to L_B when L_B is other than a covalent bond,
- 35 (iii) alkynyl of one to twelve carbons,
 provided that a carbon of a carbon-carbon triple bond is not
 attached directly to L_B when L_B is other than a covalent bond,

where (i), (ii), and (iii) can be optionally substituted with

cycloalkyl of three to twelve carbons,

-OH,

provided that no two -OH groups are attached to the same

carbon,

aryl, and

heterocycle,

(iv) aryl,

(v) aryl substituted with 1, 2, 3, 4, or 5 substituents

independently selected from

alkyl of one to twelve carbons,

halo,

-NO₂, and

-OH,

provided that no two -OH groups are attached to the

same carbon,

(vi) heterocycle, and

(vii) heterocycle substituted with 1, 2, 3, 4, or 5 substituents

independently selected from

alkyl of one to twelve carbons,

halo,

-NO₂, and

-OH,


provided that no two -OH groups are attached to the

same carbon,

(x) -X'C(X)X''R₁₀,

(y) -C(=NR₇)OR₁₀, and

(z) -NR₇(X)NR₈R₉,



(9)

provided that when R₅ is (9), L₃ is other than -NR₇- or -O-,

where the carbon-carbon double bond is in the Z or E configuration, and

R₁₉, R₂₀, and R₂₁ are independently selected from


(a) hydrogen,

(b) halo,

(c) alkyl of one to twelve carbons, and

- (d) alkyl of one to twelve carbons substituted with
- (i) alkoxy of one to twelve carbons,
 - (ii) -OH,
provided that no two -OH groups are attached to the same carbon,
 - (iii) -SH,
provided that no two -SH groups are attached to the same carbon,
 - (iv) -CN,
 - (v) halo,
 - (vi) -CHO,
 - (vii) -NO₂,
 - (viii) haloalkoxy of one to twelve carbons,
 - (ix) perfluoroalkoxy of one to twelve carbons,
 - (x) -NR₈R₉,
 - (xi) =NNR₈R₉,
 - (xii) -NR₇NR₈R₉,
 - (xiii) -CO₂R₁₀,
 - (xiv) -C(X)NR₈R₉,
 - (xv) =N-OR₁₀,
 - (xvi) =NR₁₀,
 - (xvii) -S(O)_tR₁₀,
 - (xviii) -X'C(X)R₁₀,
 - (xix) (=X),
 - (xx) -O-(CH₂)_q-Z-R₁₀,
 - (xxi) -OC(X)NR₈R₉,
 - (xxii) -L_BR₃₀,
 - (xxiii) alkanoyloxy where the alkyl group is one to twelve carbons,
 - (xxiv) -OSO₂R₁₁, and
 - (xxv) -NR₇(X)NR₈R₉, or

R₂₀ and R₂₁ together are selected from

- (a) cycloalkyl of three to twelve carbon atoms,
- (b) cycloalkenyl of four to twelve carbon atoms, and
- (c)  (allene) where R₂₂ and R₂₃ are independently hydrogen or alkyl of one to twelve carbons, and


(10) cycloalkenyl of four to twelve carbons

where the cycloalkenyl group or the ring formed by R₂₀ and R₂₁ together can be optionally substituted with one or two substituents independently selected from


- 5 (a) alkoxy of one to twelve carbons,
- (b) -OH,
provided that no two -OH groups are attached to the same carbon,
- (c) -SH,
provided that no two -SH groups are attached to the same carbon,
- 10 (d) -CN,
- (e) halo,
- (f) -CHO,
- (g) -NO₂,
- (h) haloalkoxy of one to twelve carbons,
- 15 (i) perfluoroalkoxy of one to twelve carbons,
- (j) -NR₈R₉,
- (k) =NNR₈R₉,
- (l) -NR₇NR₈R₉,
- (m) -CO₂R₁₀,
- 20 (n) -C(X)NR₈R₉,
- (o) =N-OR₁₀,
- (p) =NR₁₀,
- (q) -S(O)_tR₁₀,
- (r) -X'C(X)R₁₀,
- 25 (s) (=X),
- (t) -O-(CH₂)_q-Z-R₁₀,
- (u) -OC(X)NR₈R₉,
- (v) -L_BR₃₀,
- (w) alkanoyloxy where the alkyl group is one to twelve carbons,
- 30 (x) -OSO₂R₁₁, and
- (y) -NR₇(X)NR₈R₉;

R₆ is hydrogen or alkyl of one to twelve carbon atoms; or

35 -L₂-R₅ and R₆ together are

- (1)  where d is 1, 2, 3, or 4 and A is selected from

- (a) $-\text{CH}_2-$,
 (b) $-\text{O}-$,
 (c) $-\text{S}(\text{O})_t$, and
 (d) $-\text{NR}_7-$, or

- (2)  where the carbon-carbon double bond can be in the E or Z configuration and R_{26} is selected from

- (a) aryl,
 (b) heterocycle,
 (c) alkyl of one to twelve carbons,
 (d) cycloalkyl of three to twelve carbons,
 (e) cycloalkenyl of four to twelve carbons, and
 (f) cycloalkenyl of four to twelve carbons where (a)-(f) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
- (i) alkoxy of one to twelve carbons,
 (ii) $-\text{OH}$,
 provided that no two $-\text{OH}$ groups are attached to the same carbon,
 (iii) $-\text{SH}$,
 provided that no two $-\text{SH}$ groups are attached to the same carbon,
 (iv) $-\text{CN}$,
 (v) halo,
 (vi) $-\text{CHO}$,
 (vii) $-\text{NO}_2$,
 (viii) haloalkoxy of one to twelve carbons,
 (ix) perfluoroalkoxy of one to twelve carbons,
 (x) $-\text{NR}_8\text{R}_9$,
 (xi) $=\text{NNR}_8\text{R}_9$,
 (xii) $-\text{NR}_7\text{NR}_8\text{R}_9$,
 (xiii) $-\text{CO}_2\text{R}_{10}$,
 (xiv) $-\text{C}(\text{X})\text{NR}_8\text{R}_9$,

- (xv) $=N-OR_{10}$,
 (xvi) $=NR_{10}$,
 (xvii) $-S(O)_tR_{10}$,
 (xviii) $-X'C(X)R_{10}$,
 5 (xix) $(=X)$,
 (xx) $-O-(CH_2)_q-Z-R_{10}$,
 (xxi) $-OC(X)NR_8R_9$,
 (xxii) $-LBR_{30}$,
 (xxiii) alkanoyloxy where the alkyl group is one to twelve carbons,
 10 (xxiii) $-OSO_2R_{11}$, and
 (xxiv) $-NR_7(X)NR_8R_9$.

In another embodiment of the invention are disclosed methods of selectively partially antagonizing, antagonizing, agonizing or modulating the glucocorticoid receptor.

In another embodiment of the invention are disclosed methods of treating diseases comprising administering an effective amount of a compound having Formula I.

In yet another embodiment of the invention are disclosed pharmaceutical compositions containing compounds of Formula I.

Compounds of this invention include, but are not limited to,
 2,5-dihydro-11-methoxy-5-phenyl-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline,
 20 2,5-dihydro-11-methoxy-5-(2-propenyl)-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline,
 2,5-dihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline, and
 2,3,5-trihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-dimethyl-4-methylene-1H-[1]benzopyrano[3,4-f]quinoline.

Detailed Description of The Invention

Definition of Terms

The term "alkanoyl" refers to an alkyl group attached to the parent molecular group through a carbonyl group.

30 The term "alkanoyloxy" refers to an alkanoyl group attached to the parent molecular group through an oxygen atom.

The term "alkenyl" refers to a monovalent straight or branched chain group of two to twelve carbons derived from a hydrocarbon having at least one carbon-carbon double bond.

The term "alkoxy" refers to an alkyl group attached to the parent molecular group through an oxygen atom.

The term "alkoxycarbonyl" refers to an ester group, i.e. an alkoxy group attached to the parent molecular moiety through a carbonyl group.

The term "alkyl" refers to a monovalent straight or branched chain group of one to twelve carbons derived from a saturated hydrocarbon.

The term "alkylene" refers to a divalent straight or branched chain group of one to twelve carbons derived from an alkane.

5 The term "alkynyl" refers to a monovalent straight or branched chain hydrocarbon of two to twelve carbons with at least one carbon-carbon triple bond.

The term "alkynylene" refers to a divalent straight or branched chain group of two to twelve carbons derived from an alkyne.

The term "amino" refers to -NH_2 .

10 The term "aryl" refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings. The aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane or cyclopentene ring.

The term "carboxy" refers to $\text{-CO}_2\text{H}$.


15 The term "cycloalkenyl" refers to a monovalent group derived from a cyclic or bicyclic hydrocarbon of three to twelve carbons that has at least one carbon-carbon double bond.

The term "cycloalkyl" refers to a monovalent group three to twelve carbons derived from a saturated cyclic or bicyclic hydrocarbon.


The term "halo" refers to F, Cl, Br, or I.

20 The term "heterocycle" represents a represents a 4-, 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds. The term "heterocycle" also includes bicyclic, tricyclic and tetracyclic groups in which any of the
25 above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring. Heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl,
30 thiazolidinyl, thiazolyl, thienyl, thiomorpholinyl, triazolyl, and the like.

Heterocyclics also include bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group such as



Heterocyclics also include compounds of the formula



where X^* is selected from $-CH_2-$, $-CH_2O-$ and $-O-$, and Y^* is selected from $-C(O)-$ and $-(C(R''))_v-$, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3. These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, and the like.

The term "N-protected amino" refers to groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)). Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butyldiacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term "O-protected carboxy" refers to a carboxylic acid protecting ester or amide group typically employed to block or protect the carboxylic acid functionality while the reactions involving other functional sites of the compound are performed. Carboxy protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis" (1981). Additionally, a carboxy protecting group can be used as a prodrug whereby the carboxy protecting group can be readily cleaved in vivo, for example by enzymatic hydrolysis, to release the biologically active parent. Such carboxy protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields as described in U.S. Pat. No. 3,840,556 and 3,719,667.

The term "oxo" refers to $(=O)$.

The term "pharmaceutically acceptable prodrugs" represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

The term "prodrug" represents compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed.,

Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

The term "pharmaceutically acceptable salt" represents those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66:1 - 19. The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like.

Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

Compounds of the present invention can exist as stereoisomers where asymmetric or chiral centers are present. These compounds are designated by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and equal mixtures of enantiomers are designated (\pm).

Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of enantiomers on chiral chromatographic columns.

Geometric isomers can also exist in the compounds of the present invention. The present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a ring. Substituents around a carbon-carbon double bond are designated as being in the Z or E configuration where the term "Z" represents substituents on the same side of the carbon-carbon double bond and the term "E" represents substituents on opposite sides of the carbon-carbon double bond. The arrangement of substituents around a ring are designated as cis or trans where the term "cis" represents substituents on the same side of the plane of the ring and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds where the substituents are disposed on both the same and opposite sides of plane of the ring are designated cis/trans.

Methods for Radioligand Binding Studies with Human Glucocorticoid and Progesterone Receptor Cytosol

The procedure described in Anal. Biochem. 1970, 37, 244-252, hereby incorporated by reference, was used. Briefly, cytosol preparations of human glucocorticoid receptor- α [GRX] isoform and human progesterone receptor-A [PRA] isoform were obtained from Ligand Pharmaceuticals (San Diego, CA). Both receptor cDNAs were cloned into baculovirus expression vectors and expressed in insect SF21 cells. [3 H]-dexamethasone (Dex, specific activity 82-86 Ci/mmol) and [3 H]-progesterone (Prog, specific activity 97-102 Ci/mmol) were purchased from Amersham Life Sciences (Arlington Heights, IL). Glass fiber type C multiscreen MAFC NOB plates were from Millipore (Burlington, MA). Hydroxyapatite Bio-Gel HTP gel was from Bio-Rad Laboratories (Hercules, CA). Tris(hydroxymethyl)aminomethane (Tris), ethylenediaminetetraacetic acid (EDTA), glycerol, dithiothreitol (DTT) and sodium molybdate were obtained from Sigma Chemicals (St. Louis, MO). Microscint-20 scintillation fluid was from Packard Instrument (Meriden, CT).

Stock solutions (32 mM) of compounds were prepared in dimethylsulfoxide (DMSO), and 50X solutions of test compounds were prepared from the 32 mM solution with a 50:50 mixture of DMSO/ethanol. The 50X solution was then diluted with binding buffer that contained 10 mM Tris-HCl, 1.5 mM EDTA, 10% glycerol, 1 mM DTT, 20 mM sodium molybdate, pH 7.5 @ 4°C. 1% DMSO/ethanol was present in the binding assay.

GRX and PRA binding reactions were performed in Millipore Multiscreen plates. For GR binding assays, [3 H]-Dex (~35,000 dpm (~0.9 nM)), GRX cytosol (~35 μ g protein), test compounds and binding buffer were mixed in a total volume of 200 μ L and incubated at 4 °C overnight in a plate shaker. Specific binding was defined as the difference between binding of [3 H]Dex in the absence and in the presence of 1 μ M unlabelled Dex.

For PR binding assays, [^3H]Prog (~36,000 dpm (~0.8 nM)), PRA cytosol (~40 μg protein), test compounds and binding buffer were mixed in a total volume of 200 μL and incubated at 4 $^{\circ}\text{C}$ at overnight in a plate shaker. Specific binding was defined as the difference between binding of [^3H]Prog in the absence and in the presence of 3 μM unlabelled Prog.

After an overnight incubation, 50 μL of hydroxyapatite (25 % weight/volume) slurry were added to each well and plates were incubated for 10 min at $^{\circ}\text{C}$ in a plate shaker. Plates were suctioned with a Millipore vacuum manifold and each well was rinsed with 300 μL of ice-cold binding buffer. A 250 μL aliquot of Packard Microscint-20 was added to each well and the wells were shaken at room temperature for 20 minutes. The amount of radioactivity was determined with a Packard TopCount plate reader.

Determination of Inhibition Constant (K_i)

The concentration of test compounds that inhibited 50% of specific binding (IC_{50}) was determined from a Hill analysis of the competitive binding experiments. The K_i of test compounds was determined using the Cheng-Prusoff equation $K_i = \text{IC}_{50} / (1 + [\text{L}^*] / [\text{K}_L])$ where L^* is the concentration of radioligand and K_L is the dissociation constant of the radioligand determined from saturation analysis. For GRX, K_L was ~1.5 nM, and for PRA, K_L was ~4.5 nM. The inhibitory potencies of compounds of this invention and their selectivity for GR and PR receptors are shown in Table 1.

Table 1

Example Number	K_i (nM)	
	GR	PR
1	230	10000
2	640	14000
3	200	10000
4	270	8600

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or

nasal spray. The term "parenteral" administration refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise
5 pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof,
10 vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Conversely, reduced particle size may maintain biological activity.

These compositions may also contain adjuvants such as preservative, wetting
15 agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the
20 inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of
25 dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of
30 drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a
35 bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan

esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Generally dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.


Abbreviations

Abbreviations that have been used in the descriptions of the scheme and the examples that follow are: BF_3OEt_2 for boron trifluoride diethyl etherate; DMF for N,N-dimethylformamide, DMSO for dimethylsulfoxide; and THF for tetrahydrofuran.

Synthetic Methods

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention can be prepared.

Syntheses of the compounds of the present invention are described in Schemes 1 and 2.

Scheme 1

As shown in Scheme 1, methyl 2-hydroxy-3-methoxybenzoate (isovanillin) was nitrated with sodium nitrite in the presence of an acid such as trifluoroacetic acid to provide phenol 1A. 1A was then converted to the triflate 1B with reagents such as trifluoromethanesulfonic anhydride. Lithium/halogen exchange of substrates such as 2-


bromoanisole with organolithium reagents such as n-butyllithium followed by treatment of the resulting anion with a trialkyl borate such as trimethyl- or triisopropylborate and hydrolysis with strong acid such as 2M HCl provided boronic acid 1C. Condensation of 1B with 1C in the presence of a palladium catalyst such as

5 tetrakis(triphenylphosphine)palladium(0) or dichlorobis(triphenylphosphine)palladium(II) provided biphenyl 1D. Saponification 1D with a base such as lithium, sodium or potassium hydroxide provided carboxylic acid 1E. Conversion of 1E to lactone 1F was effected with Lewis acids such as BBr₃. Treatment of 1F with a non-nucleophilic base such as Cs₂CO₃ and alkylation of the resulting phenol with reagents such as dimethyl sulfate or methyl iodide

10 produced alkyl-aryl ether 1G. Reduction of the nitro group in 1G with hydrogen gas and a palladium catalyst such as 10% palladium on carbon provided aniline 1H. Conversion of 1H to 1J was accomplished by a Skraup annulation reaction. 1J was converted to methyl acetal 1K by a two-step procedure consisting of conversion of 1J to its hemiacetal with reagents such as diisobutylaluminum hydride then acid-catalyzed etherification of the

15 hemiacetal with acid such as p-toluenesulfonic acid monohydrate. 1J was also treated sequentially with Lewis acids such as BF₃·OEt₂ and organomagnesium chlorides, bromides, or iodides such as phenylmagnesium bromide to provide compounds exemplified by Example 1.

Scheme 2



Acetal 1K was also treated with nucleophiles such as allyltrimethylsilane in the presence of Lewis acids such as boron trifluoride diethyl etherate to form compounds exemplified by Example 2.

The compounds and processes of the present invention will be better understood in connection with the following examples which are intended as an illustration of and not a limitation upon the scope of the invention as defined in the appended claims.

Example 1

2,5-dihydro-11-methoxy-5-phenyl-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline

Example 1A

A solution of methyl 2-hydroxy-3-methoxybenzoate (20.0 g, 110 mmol) in trifluoroacetic acid (150 mL) at 0 °C was treated with a solution of sodium nitrate (10.2 g, 121 mmol) in water (70 mL) over a period of 45 minutes, stirred at 0 °C for 30 minutes, and poured onto ice (450 mL). The precipitate was collected by filtration, washed with cold water, and dried under vacuum to provide the designated compound.

MS (DCI/NH₃) m/z 245 (M+NH₄)⁺;
¹H NMR (300 MHz, CDCl₃) δ 11.73 (s, 1H), 8.45 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 4.04 (s, 3H), 4.01 (s, 3H).

Example 1B

Example 1A (5.74 g, 25.3 mmol) in dichloromethane (100 mL) at -40 °C was treated with diisopropylethylamine (13.2 mL, 75.9 mmol) and freshly distilled triflic anhydride (10.0 g, 35.4 mmol) via addition funnel over a period of 30 minutes, stirred for 15 minutes at -40 °C when the starting phenol had been consumed, quenched with water (30 mL), stirred at 23 °C until a homogeneous, biphasic solution formed, and treated with dichloromethane (65 mL). The organic extract was washed with sequentially with 5% hydrochloric acid, brine, and saturated NaHCO₃, dried (Na₂SO₄), filtered, and concentrated. Recrystallization from hot hexanes provided the desired compound. The residue was purified by flash chromatography with 15% ethyl acetate/hexanes to provide the desired compound that can be stored indefinitely under nitrogen at -10 °C without detectable decomposition.

mp 84-86 °C

MS (DCI/NH₃) m/z 377 (M+NH₄)⁺;
¹H NMR (300 MHz, CDCl₃) δ 8.46 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 7.7 Hz, 1H), 4.06 (s, 3H), 4.01 (s, 3H);
¹³C NMR (75 MHz, CDCl₃) δ 162.4, 152.6, 146.6, 141.4, 126.4, 120.6, 118.1, 111.1, 57.1, 53.2;

Anal. calcd for C₁₀H₈F₃NO₈S: C, 33.43; H, 2.24; N, 3.89. Found: C, 33.69; H, 2.27; N, 3.81.

Example 1C

A solution of 2-bromoanisole (31.6 g, 169 mmol) in THF (320 mL) at -78 °C was treated with n-butyllithium (74.3 mL of a 2.5 M solution in hexanes, 186 mmol) for 30 minutes, stirred at -78 °C for 30 minutes, treated with triisopropylborate (48.7 mL, 211 mmol) in diethyl ether (20 mL) for 45 minutes, stirred for 30 minutes at -78 °C, stirred at 23

°C for 2 hours, poured into a mixture of ice (150 mL), 3M HCl (150 mL), and ethyl acetate (600 mL), and stirred vigorously until a homogenous biphasic solution (pH 2) formed. The layers were separated, and the organic extract was dried (Na₂SO₄), filtered, concentrated, refiltered, and washed with hexanes (2 x 30 mL) to provide the desired compound. (Note: Slow addition of triisopropylborate is essential for the avoidance of side-products resulting from overaddition of the organolithium. The boronic acid was dried under vacuum briefly (30 minutes) then stored under nitrogen until use.)

MS (DCI/NH₃) m/z 170 (M+NH₄)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.67 (s, 2H), 7.57 (dd, J=7.3, 1.3 Hz, 1H), 7.87 (ddd, J=7.9, 7.4, 1.4 Hz, 1H), 6.98-6.91 (m, 2H), 3.81 (s, 3H).

Example 1D

A mechanically stirred mixture of Example 1B (7.22 g, 20.1 mmol), Example 1C (1.98 g, 13.1 mmol, 0.65 equiv), and potassium phosphate (8.53 g, 40.2 mmol) were treated sequentially with anhydrous dioxane (85 mL) and tetrakis(triphenylphosphine)palladium(0) catalyst (1.13 g, 1.00 mmol), heated at reflux for 18 hours, treated with two portions of Example 1C (1.98 g each) at 6 and 12 hour intervals, cooled to 23 °C, and partitioned between ethyl acetate (300 mL) and water (100 mL). The organic layer was washed with 10% NaOH (50 mL) and brine (50 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography with 20% ethyl acetate/hexanes to provide the desired compound.

mp 137.5-140° C;

MS (DCI/NH₃) m/z 335 (M+NH₄)⁺ and 318 (M+H)⁺;

¹H NMR (300 MHz, CDCl₃) δ 8.36 (d, J=2.2 Hz, 1H), 7.93 (d, J=2.2 Hz, 1H), 7.39 (ddd, J=8.4, 7.5, 1.5 Hz, 1H), 7.12 (dd, J=7.5, 1.7 Hz, 1H), 7.04 (td, J=7.5, 1.6 Hz, 1H), 6.97 (d, J=8.5 Hz, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 3.65 (s, 3H);

Anal. calcd for C₁₆H₁₅NO₆: C, 60.56; H, 4.76; N, 4.41. Found: C, 60.64; H, 4.51; N, 4.39.

Example 1E

A solution of Example 1D (2.08 g, 6.55 mmol) in THF (10 mL) at 23 °C was treated with methanol (10 mL) and 20% KOH (10 mL), stirred at 23 °C for 6 hours, diluted with ethyl acetate (30 mL) and water (20 mL), and partitioned. The organic extract was extracted with water (10 mL) and the combined aqueous portions were cooled in ice water, acidified to pH 2 by dropwise treatment with 6M HCl, filtered, and washed in cold water (10 mL). The residue was dried under vacuum to provide the desired compound.

MS (DCI/NH₃) m/z 321 (M+NH₄)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 13.01 (br s, 1H), 8.12 (d, J=2.2 Hz, 1H), 7.96 (d, J=2.2 Hz, 1H), 7.33 (ddd, J=8.4, 7.6, 1.7 Hz, 1H), 7.08-7.02 (m, 2H), 6.97 (td, J=7.5, 1.2 Hz, 1H), 3.82 (s, 3H), 3.65 (s, 3H).

Example 1F

Example 1E (2.96 g, 9.75 mmol) in anhydrous dichloromethane (50 mL) at -78 °C was treated with boron tribromide (5.53 mL, 58.5 mmol, 6 equiv), warmed to 23 °C at which time all the boron tribromide went into solution to form a deep reddish-orange, homogenous solution, stirred at 23 °C for 12 hours, and then recooled to -78 °C, and quenched by the addition of anhydrous methanol (15 mL). The cooling bath was removed after 2 hours of stirring at -78 °C, and the reaction mixture was concentrated to remove trimethyl borate formed during the quench. The residue was treated with dichloromethane (30 mL) and methanol (3 mL), cooled to 0 °C, and filtered to provide the desired compound. The filtrate was concentrated to provide a second crop of the desired compound.

mp >270 °C;

MS (DCI/NH₃) m/z 275 (M+NH₄)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 12.11 (s, 1H), 9.0 (d, J=8.2 Hz, 1H), 8.37 (d, J=2.2 Hz, 1H), 8.04 (d, J=2.2 Hz, 1H), 7.62 (t, J=7.6 Hz, 1H), 7.46-7.38 (m, 2H).

Example 1G

A solution of Example 1F (279 mg, 1.08 mmol) and anhydrous cesium carbonate (495 mg, 1.52 mmol) in dry DMF (5 mL) at 23 °C was treated dropwise with methyl iodide (95 mL, 1.5 mmol), stirred at 23 °C for 2.5 hours, diluted with water (3 mL) and 1:1 ethyl acetate/hexane (20 mL), and stirred for 15 minutes. The solids which formed at the interface of the biphasic mixture were filtered, washed with water (3 mL), and dried under vacuum to provide the desired compound.

mp 250-253 °C;

MS (DCI/NH₃) m/z 289 (M+NH₄)⁺;

¹H NMR (300 MHz, CDCl₃) δ 9.01 (dd, J=7.9, 1.4 Hz, 1H), 8.94 (d, J=2.0 Hz, 1H), 8.13 (d, J=2.1 Hz, 1H), 7.59 (ddd, J=7.9, 7.4, 1.6 Hz, 1H), 7.41 (dd, J=7.7, 1.6 Hz, 1H), 7.37 (ddd, J=7.7, 7.4, 1.4 Hz, 1H), 4.22 (s, 3H).

Example 1H

A solution of Example 1G (241 mg, 0.888 mmol) in dry dioxane (7 mL) at 23 °C was treated with 10% palladium on carbon (25 mg). A reflux condenser was attached to the reaction vessel with three-way adapter equipped with a hydrogen balloon. The solution was

heated at 60°C and subjected to three purge/fill cycles with hydrogen, hydrogenated at atmospheric pressure for 24 hours, filtered through Celite® while hot, and rinsed through with additional hot THF (2 x 20 mL). The filtrate was concentrated to provide the desired compound.

5 mp 230-235°C;

MS (DCI/NH₃) m/z 259 (M+NH₄)⁺, 242 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.75 (dd, J=7.4, 1.9 Hz, 1H), 7.38-7.25 (m, 3H), 7.13 (d, J=2.3 Hz, 1H), 6.82 (d, J=2.3 Hz, 1H), 5.99 (br s, 2H), 3.98 (s, 3H).

10 Example 1J

A solution of Example 1H (202 mg, 0.837 mmol), acetone (HPLC grade, 30 mL), and iodine (70 mg, 0.276 mmol) were sealed in an ACE glass high pressure vessel (250 mL), placed in a preheated oil bath (105 °C), stirred for 10 hours at 105 °C, cooled to 23 °C, and concentrated. The resulting brown oil was purified by flash chromatography with 5%-
15 10%-30% ethyl acetate/ hexanes) to provide the desired compound.

mp 229-231 °C;

MS (DCI/NH₃) m/z 339 (M+NH₄)⁺, 322 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.76 (dd, J=8.1, 1.4 Hz, 1H), 7.35 (td, J=8, 0, 1.5 Hz, 1H), 7.30-7.22 (m, 2H), 6.95 (br s, 1H), 6.82 (s, 1H), 5.36 (br s, 2H), 3.97 (s, 3H),
20 1.90 (s, 3H), 1.22 (s, 6H);

HRMS (FAB/NBA) calcd for C₂₀H₂₀NO₃ (M+H)⁺ 322.1443. Found: 322.1430;

Anal. calcd for C₂₀H₁₉NO₃: C, 74.75; H, 5.96; N, 4.36. Found: C, 74.71; H, 5.92; N, 4.40.

25 Example 1K

A solution of Example 1J (340 mg, 1.06 mmol) in anhydrous dichloromethane (10 mL) at -78 °C was treated dropwise with diisobutylaluminum hydride (2.22 mL of a 1.0 M solution in toluene, 2.22 mmol) for 20 minutes, stirred at -78 °C for 1 hour at which time TLC analysis of the reaction mixture (quenched with satd.NH₄Cl) indicated nearly complete
30 conversion to the desired lactol and a small amount of diol resulting from over-reduction of the lactone. The solution was quenched with saturated sodium potassium tartrate (Rochelle's salt solution, 5 mL), warmed to room temperature, quenched with ethyl acetate (25 mL) and additional saturated sodium potassium tartrate (10 mL) and stirred vigorously until a homogeneous, biphasic solution resulted. The layers were separated and the aqueous
35 layer was extracted with ethyl acetate (2 x 10 mL). The organic portions were combined, washed with brine (10 mL), and dried (Na₂SO₄), filtered and concentrated to provide the crude lactol.

The crude lactol was suspended in methanol (20 mL) at 0° C, treated with p-toluenesulfonic acid monohydrate (35 mg, 10% w/w), stirred for 1 hour, warmed to 10 °C, poured into saturated NaHCO₃ (20 mL), and extracted with ethyl acetate (2 x 45 mL). The extracts were washed with brine (10 mL), (Na₂SO₄), filtered and concentrated. The residue was purified by flash chromatography with 30% hexanes/dichloromethane to provide the desired compound.

MS (DCI/NH₃) m/z 306 (M-OCH₃)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.18 (dd, J=8.0, 1.4 Hz, 1H), 7.16-6.96 (m, 3H), 6.47 (s, 1H), 6.33 (s, 1H), 5.38 (br s, 1H), 5.08 (s, 1H), 3.81 (s, 6H), 2.18 (s, 3H), 1.27 (s, 3H), 1.06 (s, 3H).

Example 1L

2,5-dihydro-11-methoxy-5-phenyl-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline

A solution of Example 1K (94 mg, 0.278 mmol) in dichloroethane (12 mL) at -10 °C was treated with freshly distilled BF₃OEt₂ (96 mL, 0.780 mmol), stirred at -10 °C for 5 minutes, treated dropwise with phenylmagnesium bromide (279 mL of a 3.0 M solution) in diethyl ether (0.834 mmol), stirred for 30 minutes at -10 °C, poured into saturated NaHCO₃ (10 mL) and extracted with ethyl acetate (2 x 25 mL). The extract was washed with brine (5 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography with toluene to provide the desired compound.

MS (DCI/NH₃) m/z 384 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.01 (dd, J=7.9, 1.3 Hz, 1H), 7.23-7.13 (m, 5H), 6.90 (td, J=7.7, 1.2 Hz, 1H), 6.83-6.72 (m, 2H), 6.78 (s, 1H), 6.48 (s, 1H), 6.34 (br s, 1H), 5.29 (s, 1H), 3.83 (s, 3H), 1.82 (s, 3H), 1.23 (s, 3H), 1.19 (s, 3H);

HRMS (FAB/NBA) calcd for C₂₆H₂₅NO₂ M⁺: 383.1885. Found: 383.1875.

Example 2

2,5-dihydro-11-methoxy-5-(2-propenyl)-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline

A solution of Example 1K (102 mg, 0.302 mmol) and trimethylallylsilane (288 mL, 1.81 mmol) in dichloromethane (6 mL) at -78 °C was treated with freshly distilled BF₃OEt₂ (112 mL, 0.907 mmol), warmed to 23 °C, stirred for 1.5 hours, poured into saturated NaHCO₃ (5 mL), and extracted with ethyl acetate (2 x 20 mL). The extract was washed with brine (3 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography with 100% toluene to provide the desired compound.

mp 84-86 °C;

MS (DCI/NH₃) m/z 348 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.14 (dd, J=7.9, 1.3 Hz, 1H), 7.08 (td, J=7.8, 1.3 Hz, 1H), 6.95 (t, J=7.7 Hz, 1H), 6.84 (d, J=7.8 Hz, 1H), 6.37 (s, 1H), 6.28 (s, 1H), 5.88-5.73 (m, 2H), 5.35 (s, 1H), 5.06-4.94 (m, 2H), 3.81 (s, 3H), 2.47-2.31 (m, 2H), 2.13 (s, 3H), 1.21 (s, 3H), 1.13 (s, 3H);

5 Anal. calcd for C₂₃H₂₅NO: C, 79.51; H, 7.25; N, 4.03. Found: C, 79.48; H, 7.18; N, 3.97.

Example 3

2,5-dihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-trimethyl-1H-[1]benzopyran[3,4-f]quinoline

10

A mixture of magnesium turnings (194 mg, 8.00 mmol) and 1-bromo-3,5-dichlorobenzene, (1.81 g, 8.00 mmol) diethyl ether (10 mL) was treated with a trace of iodine and stirred at gentle reflux for 2 hours at which point all of the magnesium had been consumed. The solution of Grignard reagent was stored under nitrogen and processed

15

immediately with Example 1K as in Example 1L to provide the desired compound.
¹H NMR (300 MHz, DMSO-d₆) δ 8.04 (dd, J=7.7, 1.2 Hz, 1H), 7.52-7.43 (m, 1H), 7.13 (dd, J=7.8, 1.3 Hz, 1H), 7.00-6.78 (m, 4H), 6.80 (s, 1H), 6.52 (s, 1H), 6.47 (br s, 1H), 5.32 (br s, 1H), 3.85 (s, 3H), 1.82 (s, 3H), 1.22 (s, 3H), 1.18 (s, 3H);
HRMS (FAB/NBA) calcd for C₂₆H₂₃Cl₂NO₂ M⁺: 451.1106. Found: 451.1117.

20

Example 4

2,3,5-trihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-dimethyl-4-methylene-1H-[1]benzopyran[3,4-f]quinoline

Example 1K and 3,5-dichlorophenylmagnesium bromide were processed as in

25


examples 1L and 3 to provide the title compound.
MS (DCI/NH₃) m/z 452 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.04 (dd, J=7.7, 1.2 Hz, 1H), 7.50-7.42 (m, 1H), 7.19-7.13 (m, 2H), 7.01-6.77, m, 4H), 6.70 (br s, 1H), 6.52 (s, 1H), 6.39 (s, 1H), 4.79 (br s, 1H), 1.82 (s, 3H), 2.38-2.11 (m, 2H), 1.22 (s, 3H), 1.18 (s, 3H);

30 HRMS (FAB/NBA) calcd for C₂₆H₂₃Cl₂NO₂·(M⁺): 451.1106. Found: 451.1098.

WHAT IS CLAIMED IS:

1. A compound having Formula I



I,

or pharmaceutically acceptable salts or prodrugs thereof, where the symbol --- represents a single or double bond, provided that no two double bonds are in adjacent positions;

A is $\text{---L}_1\text{---R}_A$ where L_1 is selected from

- (1) a covalent bond,
- (2) ---O--- ,
- (3) $\text{---S(O)}_t\text{---}$ where t is 0, 1, or 2,
- (4) ---C(X)--- ,
- (5) $\text{---NR}_7\text{---}$ where R_7 is selected from
 - (a) hydrogen,
 - (b) aryl
 - (c) cycloalkyl of three to twelve carbons,
 - (d) alkanoyl where the alkyl part is one to twelve carbons,
 - (e) alkoxycarbonyl where the alkyl part is one to twelve carbons,
 - (f) alkoxycarbonyl where the alkyl part is one to twelve carbons and is substituted by 1 or 2 aryl groups,
 - (g) alkyl of one to twelve carbons,
 - (h) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
 - (i) alkenyl of three to twelve carbons, provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
 - (j) alkynyl of three to twelve carbons, provided that a carbon of a carbon-carbon triple bond is not

attached directly to nitrogen,

- (6) $-\text{NR}_8\text{C}(\text{X})\text{NR}_9-$ where X is O or S and R_8 and R_9 are independently selected from

- (a) hydrogen,
- (b) aryl,
- (c) cycloalkyl of three to twelve carbons,
- (d) alkyl of one to twelve carbons,
- (e) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
- (f) alkenyl of three to twelve carbons, provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
- (g) alkynyl of three to twelve carbons, provided that a carbon of a carbon-carbon triple bond is not attached directly to nitrogen,

- (7) $-\text{X}'\text{C}(\text{X})-$ where X is previously defined and X' is O or S,

- (8) $-\text{C}(\text{X})\text{X}'-$,

- (9) $-\text{X}'\text{C}(\text{X})\text{X}''-$ where X and X' are previously defined and X'' is O or S,

provided that when X is O, at least one of X' or X'' is O,

- (10) $-\text{NR}_8\text{C}(\text{X})-$,

- (11) $-\text{C}(\text{X})\text{NR}_8-$,

- (12) $-\text{NR}_8\text{C}(\text{X})\text{X}'-$,

- (13) $-\text{X}'\text{C}(\text{X})\text{NR}_8-$,

- (14) $-\text{SO}_2\text{NR}_8-$,

- (15) $-\text{NR}_8\text{SO}_2-$, and

- (16) $-\text{NR}_8\text{SO}_2\text{NR}_9-$

where (6)-(16) are drawn with their right ends attached to R_A and R_A is selected from

- (1) $-\text{OH}$,
- (2) $-\text{OG}$ where G is a $-\text{OH}$ protecting group,
- (3) $-\text{SH}$,
- (4) $-\text{CN}$,
- (5) halo,
- (6) haloalkoxy of one to twelve carbons,
- (7) perfluoroalkoxy of one to twelve carbons,

- (8) -CHO,
- 70 (9) -NR₇R₇ where R₇ is defined previously and R₇ is selected from
- (a) hydrogen,
 - (b) aryl,
 - (c) cycloalkyl of three to twelve carbons,
 - (d) alkanoyl where the alkyl part is one to twelve carbons,
 - 75 (e) alkoxycarbonyl where the alkyl part is one to twelve carbons,
 - (f) alkoxycarbonyl where the alkyl part is one to twelve carbons and is substituted by 1 or 2 aryl groups,
 - (g) alkyl of one to twelve carbons,
 - (h) alkyl of one to twelve carbons substituted with 1 or 2 substituents
 - 80 independently selected from aryl or cycloalkyl of three to twelve carbons,
 - (i) alkenyl of three to twelve carbons,
provided that a carbon of a carbon-carbon double bond is not attached directly to nitrogen,
 - 85 (j) alkynyl of three to twelve carbons,
provided that a carbon of a carbon-carbon triple bond is not attached directly to nitrogen,
- (10) -C(X)NR₈R₉,
- (11) -OSO₂R₁₁ where R₁₁ is selected from
- 90 (a) aryl,
 - (b) cycloalkyl of three to twelve carbons,
 - (c) alkyl of one to twelve carbons,
 - (d) alkyl of one to twelve carbons substituted with 1, 2, 3, or 4 halo substituents, and
 - 95 (e) perfluoroalkyl of one to twelve carbons,
- provided that when R_A is (1)-(11), L₁ is a covalent bond,
- (12) alkyl of one to twelve carbons,
 - (13) alkenyl of two to twelve carbons,
provided that a carbon of a carbon-carbon double bond is not attached
 - 100 directly to L₁ when L₁ is other than a covalent bond,
 - (14) alkynyl of two to twelve carbons,
provided that a carbon of a carbon-carbon triple bond is not attached
 - directly to L₁ when L₁ is other than a covalent bond,
- where (12), (13), and (14) can be optionally substituted with 1, 2, or 3 substituents
- 105 independently selected from

- (a) alkoxy of one to twelve carbons,
(b) -OH,
provided that no two -OH groups are attached to the same carbon,
(c) -SH,
provided that no two -SH groups are attached to the same carbon,
(d) -CN,
(e) halo,
(f) -CHO,
(g) -NO₂,
(h) haloalkoxy of one to twelve carbons,
(i) perfluoroalkoxy of one to twelve carbons,
(j) -NR₇R_{7'},
(k) =NNR₇R_{7'},
(l) -NR₇NR_{7'}R_{7''} where R₇ and R_{7'} are defined previously and
R_{7''} is selected from
(i) hydrogen,
(ii) aryl,
(iii) cycloalkyl of three to twelve carbons,
(vi) alkanoyl where the alkyl part is one to twelve carbons,
(v) alkoxycarbonyl where the alkyl part is one to twelve carbons,
(vi) alkoxycarbonyl where the alkyl part is one to twelve carbons substituted by 1 or 2 aryl groups,
(vii) alkyl of one to twelve carbons,
(viii) alkyl of one to twelve carbons substituted with 1 or 2 substituents independently selected from aryl or cycloalkyl of three to twelve carbons,
(ix) alkenyl of three to twelve carbons,
provided that a carbon-carbon double bond is not attached directly to nitrogen, and
(x) alkynyl of three to twelve carbons,
provided that a carbon-carbon triple bond is not attached directly to nitrogen,
(m) -CO₂R₁₀ where R₁₀ is selected from
(i) aryl,
(ii) aryl substituted with 1, 2, or 3 alkyl of one to twelve carbon substituents,

- 145 (ii) cycloalkyl of three to twelve carbons,
 (iii) alkyl of one to twelve carbons, and
 (iv) alkyl of one to twelve carbons substituted with aryl or
 cycloalkyl of three to twelve carbons,
- (n) $-C(X)NR_8R_9$,
 (o) $=N-OR_{10}$,
 (p) $=NR_{10}$,
 150 (q) $-S(O)_tR_{10}$,
 (r) $-X'C(X)R_{10}$,
 (s) $(=X)$, and
 (t) $-OSO_2R_{11}$.
- (15) cycloalkyl of three to twelve carbons,
 155 (16) cycloalkenyl of four to twelve carbons,
 provided that a carbon of a carbon-carbon double bond is not attached
 directly to L_1 when L_1 is other than a covalent bond,
 where (15) and (16) can be optionally substituted with 1, 2, 3, or 4 substituents
 independently selected from
- 160 (a) alkyl of one to twelve carbons,
 (b) aryl,
 (c) alkoxy of one to twelve carbons,
 (d) halo, and
 (e) $-OH$,
 165 provided that no two $-OH$ groups are attached to the same carbon,
- (17) perfluoroalkyl of one to twelve carbons,
 (18) aryl, and
 (19) heterocycle
 where (18) and (19) can be optionally substituted with 1, 2, 3, 4, or 5 substituents
 independently selected from
- 170 (a) alkyl of one to twelve carbons,
 (b) alkanoyloxy where the alkyl part is one to twelve carbons,
 (c) alkoxycarbonyl where the alkyl part is one to twelve carbons,
 (d) alkoxy of one to twelve carbons,
 175 (e) halo,
 (f) $-OH$,
 provided that no two $-OH$ groups are attached to the same carbon,
 (g) thioalkoxy of one to twelve carbons,
 (h) perfluoroalkyl of one to twelve carbons,

- 180 (i) $-\text{NR}_7\text{R}_7'$,
 (j) $-\text{CO}_2\text{R}_{10}$,
 (k) $-\text{OSO}_2\text{R}_{11}$, and
 (l) $(=\text{X})$;

185 R_1 , R_2 , R_3 , and R_4 are independently hydrogen or A; or

R_1 and R_2 together are $-\text{X}^*-\text{Y}^*-\text{Z}^*$ where X^* is $-\text{O}-$ or $-\text{CH}_2-$, Y^* is $-\text{C}(\text{O})-$ or $-(\text{C}(\text{R}_{12})(\text{R}_{13}))_v-$ where R_{12} and R_{13} are independently hydrogen or alkyl of one to twelve carbons and v is 1, 2, or 3, and Z^* is selected from $-\text{CH}_2-$, $-\text{CH}_2\text{S}(\text{O})_t-$,
 190 $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NR}_7-$, $-\text{NR}_7-$, and $-\text{O}-$;

L_2 is selected from

- (1) a covalent bond,
 (2) alkylene of one to twelve carbons,
 195 (3) alkylene of one to twelve carbons substituted with 1 or 2 substituents independently selected from
 (a) spiroalkyl of three to eight carbon atoms,
 (b) spiroalkenyl of five or eight carbon atoms,
 (c) oxo,
 200 (d) halo, and
 (e) $-\text{OH}$,
 provided that no two $-\text{OH}$ groups are attached to the same carbon,
 (4) alkynylene of two to twelve carbons,
 (5) $-\text{NR}_7-$,
 205 (6) $-\text{C}(\text{X})-$,
 (7) $-\text{O}-$, and
 (8) $-\text{S}(\text{O})_t-$; and

R_5 is selected from

- 210 (1) halo,
 (2) $-\text{C}(=\text{NR}_7)\text{OR}_{10}$,
 (3) $-\text{CN}$,

provided that when R_5 is (1), (2), or (3), L_2 is a covalent bond,

- (4) alkyl of one to twelve carbons,
 215 (5) alkynyl two to twelve carbons,
 provided that a carbon of a carbon-carbon triple bond is not attached directly

to L₃ when L₃ is other than a covalent bond,

(6) cycloalkyl of three to twelve carbons,

(7) heterocycle,

220 (8) aryl

where (4)-(8) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from

(a) -OH,

provided that no two -OH groups are attached to the same carbon,

225 (b) -SH,

provided that no two -SH groups are attached to the same carbon,

(c) -CN,

(d) halo,

(e) -CHO,

230 (f) -NO₂,

(g) haloalkoxy of one to twelve carbons,

(h) perfluoroalkoxy of one to twelve carbons,

(i) -NR₈R₉ where R₈ and R₉ are selected from

(i) hydrogen,

235 (ii) alkanoyl where the alkyl part is one to twelve carbons,

(iii) alkoxycarbonyl where the alkyl part is one to twelve carbons,

(iv) alkoxycarbonyl where the alkyl part is one to twelve carbons and is substituted with 1 or 2 phenyl substituents;

(v) cycloalkyl of three to twelve carbons,

240 (vi) alkyl of one to twelve carbons,

(vii) alkyl of one to twelve carbons substituted with 1, 2, or 3 substituents independently selected from alkoxy of one to twelve carbons,

cycloalkyl of three to twelve carbons, and

245 aryl,

(viii) alkenyl of three to twelve carbons,

provided that a carbon of a carbon-carbon double bond is not directly attached to nitrogen,

(ix) alkynyl of three to twelve carbons,

250 provided that a carbon of a carbon-carbon triple bond is not directly attached to nitrogen,

(x) aryl,

(xi) aryl substituted with 1, 2, 3, 4, or 5 substituents

- independently selected from
- 255 alkyl of one to twelve carbons,
 alkanoyloxy where the alkyl part is one to twelve carbons,
 alkoxycarbonyl where the alkyl part is one to twelve carbons,
 alkoxy of one to twelve carbons,
 halo,
- 260 -OH
 provided that no two -OH groups are attached to the same
 carbon,
 thioalkoxy of one to twelve carbons,
 perfluoroalkyl of one to twelve carbons,
- 265 -NR₇R₇,
 -CO₂R₁₀,
 -OSO₂R₁₁, and
 (=X), or
- R₈' and R₉' together with the nitrogen atom to which they are
- 270 attached form a ring selected from
- (i) aziridine,
 (ii) azetidine,
 (iii) pyrrolidine,
 (iv) piperidine,
 275 (v) pyrazine,
 (vi) morpholine,
 (vii) thiomorpholine, and
 (viii) thiomorpholine sulfone
- where (i)-(viii) can be optionally substituted with 1, 2, or 3 alkyl of
- 280 one to twelve carbon substituents,
- (j) =NNR₈'R₉',
 (k) -NR₇NR₈'R₉',
 (l) -CO₂R₈,
 (m) -C(X)NR₈'R₉',
 285 (n) =N-OR₈,
 (o) =NR₈,
 (p) -S(O)_tR₁₀,
 (q) -X'C(X)R₈,
 (r) (=X),
 290 (s) -O-(CH₂)_q-Z-R₁₀ where R₁₀ is defined previously, q is 1, 2, or 3,

and Z is O or -S(O)_r-,

(t) -OC(X)NR₈R₉,

(u) -OSO₂R₁₁,

(v) alkanoyloxy where the alkyl group is one to twelve carbons,

295 (w) -L_BR₃₀ where L_B is selected from

(i) a covalent bond,

(ii) -O-,

(iii) -S(O)_r-, and

(iv) -C(X)- and

300 R₃₀ is selected from

(i) alkyl of one to twelve carbons,

(ii) alkenyl of one to twelve carbons,

provided that a carbon of a carbon-carbon double bond is not attached directly to L_B when L_B is other than a covalent bond,

305 (iii) alkynyl of one to twelve carbons,

provided that a carbon of a carbon-carbon triple bond is not attached directly to L_B when L_B is other than a covalent bond,

where (i), (ii), and (iii) can be optionally substituted with

cycloalkyl of three to twelve carbons,

310 -OH,

provided that no two -OH groups are attached to the same carbon,

aryl, and

heterocycle,

315 (iv) aryl,

(v) aryl substituted with 1, 2, 3, 4, or 5 substituents independently selected from

alkyl of one to twelve carbons,

320 halo,

-NO₂, and

-OH,

provided that no two -OH groups are attached to the same carbon,

(vi) heterocycle, and


325 (vii) heterocycle substituted with 1, 2, 3, 4, or 5 substituents independently selected from

alkyl of one to twelve carbons,

halo,
 -NO₂, and
 -OH,

provided that no two -OH groups are attached to the same carbon,

- (x) -X'C(X)X''R₁₀,
 (y) -C(=NR₇)OR₁₀, and
 (z) -NR₇(X)NR₈R₉,




(9)

provided that when R₅ is (9), L₃ is other than -NR₇- or -O-,
 where the carbon-carbon double bond is in the Z or E configuration, and
 R₁₉, R₂₀, and R₂₁ are independently selected from

- (a) hydrogen,
 (b) halo,
 (c) alkyl of one to twelve carbons, and
 (d) alkyl of one to twelve carbons substituted with
 (i) alkoxy of one to twelve carbons,
 (ii) -OH,
 provided that no two -OH groups are attached to the same carbon,
 (iii) -SH,
 provided that no two -SH groups are attached to the same carbon,
 (iv) -CN,
 (v) halo,
 (vi) -CHO,
 (vii) -NO₂,
 (viii) haloalkoxy of one to twelve carbons,
 (ix) perfluoroalkoxy of one to twelve carbons,
 (x) -NR₈R₉,
 (xi) =NNR₈R₉,
 (xii) -NR₇NR₈R₉,
 (xiii) -CO₂R₁₀,
 (xiv) -C(X)NR₈R₉,
 (xv) =N-OR₁₀,

- 365 (xvi) $=NR_{10}$,
 (xvii) $-S(O)_tR_{10}$,
 (xviii) $-X'C(X)R_{10}$,
 (xix) $(=X)$,
 (xx) $-O-(CH_2)_q-Z-R_{10}$,
 (xxi) $-OC(X)NR_8R_9$,
 (xxii) $-LBR_{30}$,
 370 (xxiii) alkanoyloxy where the alkyl group is one to twelve carbons,
 (xxiv) $-OSO_2R_{11}$, and
 (xxv) $-NR_7(X)NR_8R_9$, or

R_{20} and R_{21} together are selected from

- 375 (a) cycloalkyl of three to twelve carbon atoms,
 (b) cycloalkenyl of four to twelve carbon atoms, and
 (c)  (allene) where R_{22} and R_{23} are independently
 hydrogen or alkyl of one to twelve carbons, and

(10) cycloalkenyl of four to twelve carbons


where the cycloalkenyl group or the ring formed by R_{20} and R_{21} together can be
 380 optionally substituted with one or two substituents independently selected
 from

- (a) alkoxy of one to twelve carbons,
 (b) $-OH$,
 385 provided that no two $-OH$ groups are attached to the same carbon,
 (c) $-SH$,
 provided that no two $-SH$ groups are attached to the same carbon,
 (d) $-CN$,
 (e) halo,
 (f) $-CHO$,
 390 (g) $-NO_2$,
 (h) haloalkoxy of one to twelve carbons,
 (i) perfluoroalkoxy of one to twelve carbons,
 (j) $-NR_8R_9$,
 (k) $=NNR_8R_9$,
 395 (l) $-NR_7NR_8R_9$,
 (m) $-CO_2R_{10}$,
 (n) $-C(X)NR_8R_9$,


- 400 (o) $=N-OR_{10}$,
 (p) $=NR_{10}$,
 (q) $-S(O)_tR_{10}$,
 (r) $-X'C(X)R_{10}$,
 (s) $(=X)$,
 (t) $-O-(CH_2)_q-Z-R_{10}$,
 (u) $-OC(X)NR_8R_9$,
 405 (v) $-L_BR_{30}$,
 (w) alkanoyloxy where the alkyl group is one to twelve carbons,
 (x) $-OSO_2R_{11}$, and
 (y) $-NR_7(X)NR_8R_9$;

410 R_6 is hydrogen or alkyl of one to twelve carbon atoms; or

$-L_2-R_5$ and R_6 together are

- (1)  where d is 1, 2, 3, or 4 and A is selected from

- 415 (a) $-CH_2-$,
 (b) $-O-$,
 (c) $-S(O)_t$, and
 (d) $-NR_7-$, or

- (2)  where the carbon-carbon double bond can be in the E or Z configuration and R_{26} is selected from

- 420 (a) aryl,
 (b) heterocycle,
 (c) alkyl of one to twelve carbons,
 (d) cycloalkyl of three to twelve carbons,
 425 (e) cycloalkenyl of four to twelve carbons, and
 (f) cycloalkenyl of four to twelve carbons where (a)-(f) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
 (i) alkoxy of one to twelve carbons,
 430 (ii) $-OH$,
 provided that no two $-OH$ groups are attached to the same

- carbon,
- (iii) -SH,
provided that no two -SH groups are attached to the same
carbon,
- (iv) -CN,
- (v) halo,
- (vi) -CHO,
- (vii) -NO₂,
- (viii) haloalkoxy of one to twelve carbons,
- (ix) perfluoroalkoxy of one to twelve carbons,
- (x) -NR₈R₉,
- (xi) =NNR₈R₉,
- (xii) -NR₇NR₈R₉,
- (xiii) -CO₂R₁₀,
- (xiv) -C(X)NR₈R₉,
- (xv) =N-OR₁₀,
- (xvi) =NR₁₀,
- (xvii) -S(O)_tR₁₀,
- (xviii) -X'C(X)R₁₀,
- (xix) (=X),
- (xx) -O-(CH₂)_q-Z-R₁₀,
- (xxi) -OC(X)NR₈R₉,
- (xxii) -L_BR₃₀,
- (xxiii) alkanoyloxy where the alkyl group is one to twelve carbons,
- (xxiii) -OSO₂R₁₁, and
- (xxiv) -NR₇(X)NR₈R₉.

2. A compound according to Claim 1 where

A is -L₁-R_A where

L₁ is selected from

- (1) -O-,
- (2) -C(X)X'- where X and X' are O,
- (3) -X'C(X)- where X and X' are O, and
- (4) -X'C(X)X''- where X, X', and X'' are O and

R_A is selected from

- (1) alkyl of one to twelve carbons,
- (2) alkenyl of three to twelve carbons, and

(3) alkynyl of three to twelve carbons where (1)-(3) can be optionally substituted;

R_1 is hydrogen or $-L_1-R_A$ where

15 L_1 is selected from

- (1) a covalent bond,
- (2) $-O-$,
- (3) $-C(X)X'-$ where X and X' are O,
- (4) $-X'C(X)-$ where X and X' are O, and
- 20 (5) $-X'C(X)X''-$ where X , X' , and X'' are O and

R_A is selected from

- (1) alkyl of one to twelve carbons,
- (2) alkenyl of two to twelve carbons,
- (3) alkynyl of two to twelve carbons where (1)-(3) can be optionally substituted,
- 25 (4) $-OH$, and
- (5) $-NR_7R_7$;

R_2 is hydrogen or $-L_1-R_A$ where L_1 is $-O-$ and R_A is alkyl of one to twelve carbons;

30


R_3 and R_4 are hydrogen;

L_2 is selected from

- (1) covalent bond,
- 35 (2) alkylene of one to twelve carbons, and
- (3) $-NR_7-$;


R_5 is selected from

- (1) halo,
- 40 (2) $-C(=NR_7)OR_{10}$,
- (3) $-CN$,
- (4) alkyl of one to twelve carbons,
- (5) alkynyl of two to twelve carbons,
- (6) heterocycle,
- 45 (7) aryl, and



R₆ is hydrogen; or


50

-L₂-R₅ and R₆ together are (=X) or  where the substituents defined by R₂₆ can be optionally substituted.

3. A compound according to Claim 2 where
A is -L₁-R_A where L₁ is O and R_A is alkyl of one to twelve carbons that can be optionally substituted;

5 R₁, R₂, R₃, and R₄ are hydrogen;

L₂ is a covalent bond or alkylene of one to twelve carbons;



R₆ is hydrogen; or

-L₂-R₅ and R₆ together are (=X).

15

4. A compound according to Claim 3 selected from
2,5-dihydro-11-methoxy-5-phenyl-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline,
2,5-dihydro-11-methoxy-5-(2-propenyl)-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline,
5 2,5-dihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinoline, and
2,3,5-trihydro-11-methoxy-5-(3,5-dichlorophenyl)-2,2,4-dimethyl-4-methylene-1H-

[1]benzopyrano[3,4-f]quinoline.

10

5. A method of selectively modulating the activation, repression, agonism, and antagonism effects of the glucocorticoid receptor in a mammal comprising administering an effective amount of a compound of Claim 1.

5 6. A method of treating inflammation and immune, autoimmune and inflammatory diseases in a mammal comprising administering an effective amount of a compound of Claim 1.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/03210

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D491/052 A61K31/44 //(C07D491/052,311:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 19458 A (LIGAND PHARMACEUTICALS) 27 June 1996 see claims 1,13 -----	1,5

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 June 1999

Date of mailing of the international search report

05/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/03210

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5,6
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 5 and 6
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/03210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9619458 A	27-06-1996	US 5688810 A	18-11-1997
		US 5688808 A	18-11-1997
		US 5693647 A	02-12-1997
		US 5696127 A	09-12-1997
		US 5693646 A	02-12-1997
		US 5696130 A	09-12-1997
		US 5696133 A	09-12-1997
		AU 4597796 A	10-07-1996
		BR 9510486 A	02-06-1998
		CA 2208347 A	27-06-1996
		CN 1175247 A	04-03-1998
		CZ 9701761 A	16-09-1998
		EP 0800519 A	15-10-1997
		JP 10510840 T	20-10-1998
		NO 972591 A	14-08-1997